NCT06754384View on ClinicalTrials.gov

Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

552

Participants

Timeline

Start Date

January 30, 2025

Primary Completion Date

January 30, 2026

Study Completion Date

August 30, 2026

Conditions
Hand, Foot, and Mouth Disease (HFMD)Herpangina
Interventions
BIOLOGICAL

Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)

Low-dose tetravalent inactivated enterovirus vaccine (Vero cell) )(only for phase Ⅰ）

BIOLOGICAL

Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)

Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)

BIOLOGICAL

High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )

High-dose tetravalent inactivated enterovirus vaccine (Vero cell) )

BIOLOGICAL

EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）

EV71 inactivated enterovirus vaccine (Vero cell) )(for ages 6-71 months）

BIOLOGICAL

placebo (for ages 6-12 years)

placebo (for ages 6-12 years)

Trial Locations (1)

Unknown

Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou

All Listed Sponsors
lead

Sinovac Biotech Co., Ltd

INDUSTRY

NCT06754384 - Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell). | Biotech Hunter | Biotech Hunter